MedTrace Logo

Microdosing LSD in Women With Premenstrual Disorders

NCT07189299 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-09-23

No results posted yet for this study

Summary

The investigators aim to investigate the role of the serotonin 2A receptor in women with premenstrual disorders. This study uses a double-blind, randomized, controlled design with 3 arms: Intervention 1: 10 micg LSD for \~10 days during the late luteal phase (for 3 cycles) Intervention 2: 10 micg LSD every other day for \~10 days during the late luteal phase (for 3 cycles) Control intervention: Placebo for \~10 days during the late luteal phase (for 3 cycles) Each participant will be treated in only one arm. The study employs a parallel design with three treatment arms and consists of a two-cycle observational phase followed by a three-cycle treatment phase.

Conditions

  • PMS
  • PMDD

Interventions

DRUG

LSD 10 μg every Day

Participants will receive 10 μg LSD every day during the luteal phase

DRUG

LSD 10 μg every other day

Participants receive 10μg LSD every second day during the luteal phase

DRUG

Placebo

Participants receive inactive placebo during the luteal phase

Sponsors & Collaborators

  • Friederike Holze

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2029-11-01
Completion
2030-01-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07189299 on ClinicalTrials.gov